Document is current
Any future updates will be listed below
-
Authors
Rash, Brian G. https://orcid.org/0000-0003-4555-4093
Ramdas, Kevin N. https://orcid.org/0009-0000-4396-0798
Agafonova, Nataliya
Naioti, Eric
McClain-Moss, Lisa
Zainul, Zarin https://orcid.org/0000-0003-3982-8123
Varnado, Brittany
Peterson, Kevin
Brown, Michael
Leal, Thiago
Kopcho, Steven
Carballosa, Raul
Patel, Paayal
Brody, Mark
Herskowitz, Brad
Fuquay, Ana
Rodriguez, Savannah
Jacobson, Alan F.
Leon, Ramon
Pfeffer, Michael
Schwartzbard, Julie B.
Botbyl, Jeffrey
Oliva, Anthony A. Jr https://orcid.org/0000-0002-3099-2421
Hare, Joshua M. https://orcid.org/0000-0002-7751-5032
- License Information
-
More Information
Article History
Received: 12 April 2024
Accepted: 29 January 2025
First Online: 10 March 2025
Competing interests
: J.M.H. reports having a patent for cardiac cell-based therapy and holds equity in Vestion and maintains a professional relationship with Vestion as a consultant and member of the Board of Directors and Scientific Advisory Board. Vestion did not play a role in the design, conduct, or funding of the study. J.M.H. is the Chief Scientific Officer, a compensated consultant and board member for Longeveron and holds equity in Longeveron. J.M.H. is also the co-inventor of intellectual property licensed to Longeveron. The University of Miami is an equity owner in Longeveron, which has licensed intellectual property from the University of Miami. B.G.R., N.A., L.M.M., Z.Z., B.V., K.P., M.B. and T.L. are active employees of Longeveron. The other authors declare no competing interests.
